公司拥有ABGENT、B-bridge、IBL-America、R&D、CST、MBL、SAB、KPL、Santa、Abnova、LifeSpan等G蛋白偶联受体109A抗体品牌全年代理权，价格行业优势明显。
英文名称 Anti-GPR109A/HM74A
中文名称 G蛋白偶联受体109A抗体 
G蛋白偶联受体109A抗体 别 名 G-protein coupled receptor 109A; GPR109A; HM74a; HM74b; NIACR1; Puma-g; PUMAG; Niacr1; Niacin receptor 1; Nicotinic acid receptor; G-protein coupled receptor 109; G-protein coupled receptor HM74; G protein coupled receptor HM74a; G protein coupled receptor Hm74b; Protein PUMA-G; Interferon gamma inducible gene Puma g; Nicotinic acid receptor 1; Nicotinic acid receptor; Puma g; Pumag; rHM74b; HCAR2_HUMAN .
浓 度 1mg/1ml
规 格 0.2ml/200μg
抗体来源 Rabbit
克隆类型 polyclonal
交叉反应 Human, Mouse, Rat, Pig, Rabbit
产品类型 一抗
研究领域 免疫学
46915L-HDC （L-Histidine decarboxylase） L-组氨酸脱羧酶抗原 0.5mg
46916LIF peptide 白血病抑制因子抗原 0.5mg
46917LIFR/CD118 peptide 白血病抑制因子受体抗原 0.5mg
46918Lingo-1 Nogo受体作用蛋白抗原 0.5mg
46919LIS1（Lissencephaly-1 protein） 无脑回的致病基因LIS1抗原 0.5mg
46920LFABP/FABP-1（Liver Fatty acid binding protein） 肝脏型脂肪酸结合蛋白抗原 0.5mg
46921LFABP/FABP-2（Liver Fatty acid binding protein） 肝脏型脂肪酸结合蛋白抗原 0.5mg
46922LN （laminin） 层粘连蛋白（多肽抗原） 0.5mg
46923Laminin Beta1 peptide 层粘连蛋白β1抗原 0.5mg
46924lamin A 核纤层蛋白A抗原 0.5mg
46925LOX-1/OLR1 凝集素样氧化型低密度脂蛋白受体 0.5mg
46926LPLUNC1 人鼻咽癌癌基因多肽抗原 0.5mg
46927LYVE-1（lymphalic vessel endotheilial hyaluronan receptor 1） 淋巴管内皮透明质酸受体抗原 0.5mg
46928ACE（ ACE, testis-specific isoform precursor） 血管紧张素转换酶（抗原） 0.5mg
46929Integrin alpha E2 peptide 整合素alpha E2抗原 0.5mg
46930Mac-1 （Mac-1/CR3/CD11b+CD18） 巨噬细胞表面分子抗原 0.5mg
46931Mafa（avian）（V-maf musculoaponeurotic fibrosarcoma oncogene homolog A） v-maf 肌腱膜纤维肉瘤癌基因同源物A抗原 0.5mg
46932MAGE-1 黑色素瘤相关 0.5mg
46933MAPKK1 （MAP kinase kinase 1） 丝裂原活化蛋白激酶激酶1抗原 0.5mg
46934ASK1/MAPKKK5 细胞凋亡信号调节激酶1/丝裂原活化蛋白激酶激酶激酶5抗原 0.5mg
46935Maspin （mammary serine protease inhibitor） 抑癌基因抗原 0.5mg
46936Matriptase 蛋白裂解酶（一种新的癌基因）抗原 0.5mg
46937HCMV UL49（Human Cytomegalovirus UL49 Gene） 人巨细胞病毒UL49抗原 0.5mg
46938MC-1R （melanocortin-1-receptor） 黑皮质素-1受体抗原 0.5ml
46939Mcl-1（myeloid cell leukemia 1） peptide 髓样细胞白血病-1抗原 0.5mg
46940MDM2 （urine double minute 2） 双微体2癌基因抗原 0.5mg
46941MDR1（multidrug resistance 1） 多药耐药蛋白抗原 0.5mg
G蛋白偶联受体109A抗体46942MEF2（myocyte enhancer-binding factor 2） 肌细胞增强因子2抗原 0.5mg
蛋白分子量 predicted molecular weight: 40kDa
性 状 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human GPR109A
亚 型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
产品应用 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
G蛋白偶联受体109A抗体产品介绍 Acts as a high affinity receptor for both nicotinic acid （also known as niacin） and （D）-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G（i）-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.
Function : Acts as a high affinity receptor for both nicotinic acid （also known as niacin） and （D）-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G（i）-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.
Subcellular Location : Cell membrane; Multi-pass membrane protein.
Tissue Specificity : Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.
Similarity : Belongs to the G-protein coupled receptor 1 family.
Database links : UniProtKB/Swiss-Prot: Q8TDS4.1